$STIM
Neuronetics Inc

2024 Q2 Form 10-Q Financial Statement

#000155837024007073 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $16.45M $17.42M
YoY Change -6.59% 12.08%
Cost Of Revenue $4.271M $4.329M
YoY Change -11.68% 4.46%
Gross Profit $12.18M $13.09M
YoY Change -4.66% 14.85%
Gross Profit Margin 74.04% 75.14%
Selling, General & Admin $18.45M $17.60M
YoY Change 3.9% -4.94%
% of Gross Profit 151.5% 134.46%
Research & Development $2.235M $2.349M
YoY Change -5.46% -15.81%
% of Gross Profit 18.35% 17.95%
Depreciation & Amortization $555.0K $560.0K
YoY Change 13.73% 8.53%
% of Gross Profit 4.56% 4.28%
Operating Expenses $20.69M $19.95M
YoY Change 2.8% -6.37%
Operating Profit -$8.507M -$6.859M
YoY Change 15.76% -30.77%
Interest Expense $1.978M $1.826M
YoY Change 72.9% 45.73%
% of Operating Profit
Other Income/Expense, Net $653.0K $812.0K
YoY Change -81.82% 26.88%
Pretax Income -$9.832M -$7.873M
YoY Change 100.61% -25.16%
Income Tax
% Of Pretax Income
Net Earnings -$9.832M -$7.873M
YoY Change 100.61% -25.16%
Net Earnings / Revenue -59.77% -45.2%
Basic Earnings Per Share -$0.33 -$0.27
Diluted Earnings Per Share -$0.33 -$0.27
COMMON SHARES
Basic Shares Outstanding 30.00M 29.76M
Diluted Shares Outstanding 30.05M 29.47M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.64M $47.73M
YoY Change -7.11% -13.91%
Cash & Equivalents $42.60M $47.70M
Short-Term Investments
Other Short-Term Assets $6.531M $7.000M
YoY Change -2.64% 62.22%
Inventory $6.142M $6.694M
Prepaid Expenses $2.739M $2.630M
Receivables $17.14M $17.50M
Other Receivables $3.048M $2.937M
Total Short-Term Assets $75.51M $81.87M
YoY Change -2.79% 0.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.728M $1.847M
YoY Change -18.03% -7.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.053M $4.883M
YoY Change 25.01% 39.79%
Total Long-Term Assets $21.31M $21.95M
YoY Change -6.2% -2.45%
TOTAL ASSETS
Total Short-Term Assets $75.51M $81.87M
Total Long-Term Assets $21.31M $21.95M
Total Assets $96.81M $103.8M
YoY Change -3.57% 0.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.102M $2.979M
YoY Change -0.99% -40.06%
Accrued Expenses $9.236M $9.045M
YoY Change 10.28% 21.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $13.61M
YoY Change
Total Short-Term Liabilities $29.26M $14.50M
YoY Change 94.72% -4.18%
LONG-TERM LIABILITIES
Long-Term Debt $46.15M $59.44M
YoY Change 25.69% 62.23%
Other Long-Term Liabilities $2.023M $2.214M
YoY Change -36.3% -36.53%
Total Long-Term Liabilities $46.15M $59.44M
YoY Change 25.69% 62.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.26M $14.50M
Total Long-Term Liabilities $46.15M $59.44M
Total Liabilities $77.43M $76.16M
YoY Change 40.99% 37.82%
SHAREHOLDERS EQUITY
Retained Earnings -$393.8M -$384.0M
YoY Change 9.0% 7.74%
Common Stock $413.2M $411.6M
YoY Change 1.57% 1.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.39M $27.66M
YoY Change
Total Liabilities & Shareholders Equity $96.81M $103.8M
YoY Change -3.57% 0.2%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$9.832M -$7.873M
YoY Change 100.61% -25.16%
Depreciation, Depletion And Amortization $555.0K $560.0K
YoY Change 13.73% 8.53%
Cash From Operating Activities -$4.969M -$12.00M
YoY Change -43.75% -21.05%
INVESTING ACTIVITIES
Capital Expenditures $616.0K $375.0K
YoY Change -12.5% 60.26%
Acquisitions
YoY Change
Other Investing Activities $497.0K $443.0K
YoY Change 701.61% 768.63%
Cash From Investing Activities -$119.0K $68.00K
YoY Change -81.46% -137.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.969M -12.00M
Cash From Investing Activities -119.0K 68.00K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -5.088M -11.93M
YoY Change -46.66% -19.83%
FREE CASH FLOW
Cash From Operating Activities -$4.969M -$12.00M
Capital Expenditures $616.0K $375.0K
Free Cash Flow -$5.585M -$12.38M
YoY Change -41.44% -19.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001227636
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
CY2024Q1 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29092000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29975000
CY2024Q1 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#MoneyMarketFundsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#MoneyMarketFundsMember
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38546
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NEURONETICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-1051425
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3222 Phoenixville Pike
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
CY2024Q1 dei City Area Code
CityAreaCode
610
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
640-4202
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock ($0.01 par value)
CY2024Q1 dei Trading Symbol
TradingSymbol
STIM
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29997563
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47730000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59677000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17504000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15782000
CY2024Q1 us-gaap Inventory Net
InventoryNet
6694000
CY2023Q4 us-gaap Inventory Net
InventoryNet
8093000
CY2024Q1 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
816000
CY2023Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
905000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2630000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2514000
CY2024Q1 stim Notes Receivables Current
NotesReceivablesCurrent
2121000
CY2023Q4 stim Notes Receivables Current
NotesReceivablesCurrent
2056000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4370000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4766000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
81865000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
93793000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1847000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2009000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2628000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2773000
CY2024Q1 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
517000
CY2023Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
661000
CY2024Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
8408000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
8370000
CY2024Q1 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
3663000
CY2023Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
3795000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4883000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4430000
CY2024Q1 us-gaap Assets
Assets
103811000
CY2023Q4 us-gaap Assets
Assets
115831000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2979000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4752000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9045000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12595000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1623000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1620000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
851000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
845000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14498000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19812000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
59444000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
59283000
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
200000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2179000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2346000
CY2024Q1 us-gaap Liabilities
Liabilities
76156000
CY2023Q4 us-gaap Liabilities
Liabilities
81641000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29975000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29092000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
300000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
291000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
411309000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
409980000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-383954000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-376081000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
27655000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
34190000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103811000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115831000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17417000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15540000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4329000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4144000
CY2024Q1 us-gaap Gross Profit
GrossProfit
13088000
CY2023Q1 us-gaap Gross Profit
GrossProfit
11396000
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11641000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11902000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5957000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6611000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2349000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2790000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
19947000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
21303000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6859000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9907000
CY2024Q1 us-gaap Interest Expense
InterestExpense
1826000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1253000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
812000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
640000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7873000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10520000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29472000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29472000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28034000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28034000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
57060000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1805000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10520000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
48345000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
34190000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1338000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7873000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
27655000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-7873000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-10520000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
560000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
516000
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
566000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
330000
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
71000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1338000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1805000
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
161000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
188000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2667000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2337000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1328000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
243000
CY2024Q1 stim Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
-234000
CY2023Q1 stim Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
-535000
CY2024Q1 stim Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
154000
CY2023Q1 stim Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
175000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-116000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-131000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1983000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2484000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3549000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-7680000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-163000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-247000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12015000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15213000
CY2024Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
375000
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
234000
CY2024Q1 stim Proceeds From Collection Issuance Of Notes Receivable
ProceedsFromCollectionIssuanceOfNotesReceivable
443000
CY2023Q1 stim Proceeds From Collection Issuance Of Notes Receivable
ProceedsFromCollectionIssuanceOfNotesReceivable
51000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
68000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-183000
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
801000
CY2023Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2500000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1200000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
499000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11947000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14897000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59677000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70340000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47730000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55443000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1666000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1064000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
210000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
52000
CY2024Q1 stim Reduction Of Accounts Receivable In Long Term Note Receivable
ReductionOfAccountsReceivableInLongTermNoteReceivable
381000
CY2023Q1 stim Reduction Of Accounts Receivable In Long Term Note Receivable
ReductionOfAccountsReceivableInLongTermNoteReceivable
6146000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.     DESCRIPTION OF BUSINESS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Neuronetics, Inc. (the “Company”) is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (“TMS”) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System was cleared in 2008 by the United States (“U.S.”) Food and Drug Administration (the “FDA”) to treat adult patients with major depressive disorder (“MDD”) who have failed to achieve satisfactory improvement from prior antidepressant medication in the current MDD episode. It is also cleared by the FDA as an adjunct for adults with obsessive-compulsive disorder (“OCD”), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as an adjunct for the treatment of MDD in adolescent patients aged 15-21. The NeuroStar Advanced Therapy System is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of March 31, 2024, the Company had cash and cash equivalents of $47.7 million and an accumulated deficit of $384.0 million. The Company incurred negative cash flows from operating activities of $12.0 million for the three months ended March 31, 2024 and $32.0 million for the year ended December 31, 2023. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company’s primary sources of capital to date have been proceeds from its initial public offering (“IPO”), private placements of its convertible preferred securities, borrowings under its credit facility, proceeds from its secondary public offering of common stock and revenues from sales of its products. As of March 31, 2024, the Company had $60.0 million of borrowings outstanding under its credit facility, which has a final maturity in <span style="-sec-ix-hidden:Hidden_shDgg87rNU23PyPRM3Uj5w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">March 2028</span></span>. Management believes that the Company’s cash and cash equivalents as of March 31, 2024 and anticipated revenues from sales of its products are sufficient to fund the Company’s operations for at least the next 12 months from the issuance of these financial statements.</p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47700000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384000000.0
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12000000.0
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32000000.0
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.     BASIS OF PRESENTATION</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (“ASUs”) promulgated by the Financial Accounting Standards Board (the “FASB”).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Interim Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with U.S. GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ equity and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three months ended March 31, 2024 are not necessarily indicative of the </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 8, 2024, wherein a more complete discussion of significant accounting policies and certain other information can be found.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The preparation of financial statements in accordance with U.S. GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ materially from estimated results.</p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The preparation of financial statements in accordance with U.S. GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ materially from estimated results.</p>
CY2024Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
18756000
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
16577000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1252000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
795000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17504000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15782000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4854000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4831000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3007000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2822000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1847000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2009000
CY2024Q1 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
4400000
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
4200000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2024Q1 us-gaap Lessee Finance Lease Lease Not Yet Commenced Description
LesseeFinanceLeaseLeaseNotYetCommencedDescription
The Company does not currently have any finance leases or executed leases that have not yet commenced.
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
275000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
267000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
659000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
898000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
921000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
882000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
116000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3476000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
446000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3030000
CY2024Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear
692000
CY2024Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
431000
CY2024Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
118000
CY2024Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
92000
CY2024Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
1333000
CY2024Q1 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
1300000
CY2024Q1 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
0
CY2024Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
20000.00
CY2023Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
40000.00
CY2024Q1 stim Amortization Period Of Deferred Sales Commissions
AmortizationPeriodOfDeferredSalesCommissions
P7Y
CY2024Q1 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
700000
CY2023Q1 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
500000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4032000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8003000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
614000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
488000
CY2024Q1 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
285000
CY2023Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
260000
CY2024Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1689000
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1760000
CY2024Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
239000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
213000
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
742000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
818000
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
567000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
877000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1053000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9045000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12595000
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.78
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.19
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.02
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.01
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
600000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
900000
CY2023Q1 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
1
CY2024Q1 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
1
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2024Q1 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1856000
CY2023Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1856000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2412000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2573000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
59444000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
59283000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
59444000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
59283000
CY2024Q1 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
1800000
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1700000
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
100000
CY2023Q1 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
1300000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1100000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
200000
CY2024Q1 us-gaap Debt Instrument Covenant Compliance
DebtInstrumentCovenantCompliance
On January 31, 2024 and February 29, 2024, the Company was not in compliance with its minimum net product revenue covenant under the Solar Facility. The Company was granted a waiver from Solar in the Solar Sixth Amendment for the covenant violations. The amount of borrowings affected by this noncompliance was $60 million.
CY2024Q1 us-gaap Debt Instrument Covenant Compliance
DebtInstrumentCovenantCompliance
On January 31, 2024 and February 29, 2024, the Company was not in compliance with its minimum net product revenue covenant under the Solar Facility. The Company was granted a waiver from Solar in the Solar Sixth Amendment for the covenant violations. The amount of borrowings affected by this noncompliance was $60 million.
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1805000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29975000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29092000
CY2024Q1 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
37509000
CY2023Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
36076000
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
41000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1338000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1

Files In Submission

Name View Source Status
0001558370-24-007073-index-headers.html Edgar Link pending
0001558370-24-007073-index.html Edgar Link pending
0001558370-24-007073.txt Edgar Link pending
0001558370-24-007073-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stim-20240331.xsd Edgar Link pending
stim-20240331x10q.htm Edgar Link pending
stim-20240331x10q005.jpg Edgar Link pending
stim-20240331xex31d1.htm Edgar Link pending
stim-20240331xex31d2.htm Edgar Link pending
stim-20240331xex32d1.htm Edgar Link pending
stim-20240331xex32d2.htm Edgar Link pending
stim-20240331_def.xml Edgar Link unprocessable
stim-20240331_lab.xml Edgar Link unprocessable
stim-20240331_pre.xml Edgar Link unprocessable
stim-20240331x10q_htm.xml Edgar Link completed
stim-20240331_cal.xml Edgar Link unprocessable